Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Accured Expenses: 2014-2025

Historic Change in Accured Expenses for ImmunityBio (IBRX) over the last 11 years, with Sep 2025 value amounting to $5.5 million.

  • ImmunityBio's Change in Accured Expenses fell 12.16% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$855,000, marking a year-over-year increase of 95.48%. This contributed to the annual value of -$1.5 million for FY2024, which is 122.54% down from last year.
  • ImmunityBio's Change in Accured Expenses amounted to $5.5 million in Q3 2025, which was down 37.30% from $8.7 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Change in Accured Expenses registered a high of $18.6 million during Q1 2023, and its lowest value of -$19.5 million during Q4 2023.
  • Its 3-year average for Change in Accured Expenses is $585,455, with a median of $3.3 million in 2024.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first spiked by 675.33% in 2022, then crashed by 519.36% in 2023.
  • Over the past 5 years, ImmunityBio's Change in Accured Expenses (Quarterly) stood at $4.6 million in 2021, then slumped by 169.13% to -$3.2 million in 2022, then tumbled by 519.36% to -$19.5 million in 2023, then skyrocketed by 89.17% to -$2.1 million in 2024, then declined by 12.16% to $5.5 million in 2025.
  • Its Change in Accured Expenses was $5.5 million in Q3 2025, compared to $8.7 million in Q2 2025 and -$12.9 million in Q1 2025.